TrialPath
Recruiting

Adaptango Performance PRocess for Older Adults Community reHabilitation

NCT07824128 · Emory University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Community-based Participatory Evaluation Studies on a Partnered Dance Program for Adults With Neurodegenerative Disease
About this study
This is a pilot study designed to assess the impact of the mediator/instructor role between dyads of older and younger adults as they engage in art and dance activities that address challenging topics. The study aims to evaluate the effects of the Adaptango Performance Process (APP) on creativity, justice, and quality of life among persons with Parkinson's disease (PWP), people living with dementia (PLWD), and young adult participants. Validated measures of creativity, justice, and quality of life will be administered before and after the intervention. The findings from this pilot phase will be used to inform the design and power calculations of future larger clinical trials intended to more definitively evaluate the effects of the APP program on creativity, engagement with challenging topics of societal importance, and psychosocial health across generations. Findings from the arts-based method evaluation will also be considered when interpreting and reporting study results.
Eligibility criteria
Inclusion Criteria: * Individuals (PWP, younger adults, PLwD) from the greater Atlanta area. Those in the PWP group must be diagnosed by a neurologist specialized in Parkinson's disease. * Score of at least 18 on the Montreal Cognitive Assessment (MoCA). Those who are in the PLwD group must score between 18 and 25 on the MoCA. Exclusion Criteria: * Acute medical illness requiring hospitalization * Uncontrolled congestive heart failure * History of stroke in the past three years * Inability to perform study procedures * Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity) * Taking medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, neurologic prescriptions to treat Multiple sclerosis. When applicable, enrollment will be delayed until dosages are stable on, e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months * Psychotic disorders * Confounding neurologic conditions \[e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness \>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae\] * Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorders within six months of evaluation * Unable to provide informed consent * Cognitively impaired individuals or individuals with impaired decision-making, individuals who are not yet adults, pregnant women, prisoners * Not able to clearly understand English
Study design
Enrollment target: 120 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-08-06
Estimated completion: 2029-09
Last updated: 2026-11-13
Interventions
Other: Adaptango Performance Process (APP) program
Primary outcomes
  • • Participants' Satisfaction of the intervention (Acceptability) (Post-intervention at 8 months)
  • • Alternate Uses Task (AUT) (Baseline, 3 months (during intervention), and 8 months (post-intervention))
Sponsor
Emory University · other
With: National Endowment for the Arts, United States
Contacts & investigators
ContactMadeleine E. Hackney, PhD · contact · mehackn@emory.edu · 314-412-4852
InvestigatorMadeleine E. Hackney, PhD · principal_investigator, Emory University
All locations (1)
Emory University, Executive Park, Wesley WoodsRecruiting
Atlanta, Georgia, United States
Adaptango Performance PRocess for Older Adults Community reHabilitation · TrialPath